Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

Completed · Phase 3

Conditions studied: Crohn's Disease

In brief

The purpose of this study is to test whether Adalimumab (at two different doses) can induce and maintain clinical remission in subjects with active Crohn's disease when compared to placebo (a substance containing no medication)

Key facts

Study ID
NCT00077779
Run by
Abbott
People needed
854
Starts
2003-07-01
Last updated by the study team
2007-09-26

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.